GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » Book Value per Share

Biotechnology Assets (XMAD:BST) Book Value per Share : €0.12 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Biotechnology Assets Book Value per Share?

Biotechnology Assets's book value per share for the quarter that ended in Dec. 2023 was €0.12.

During the past 12 months, Biotechnology Assets's average Book Value Per Share Growth Rate was 56.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 4.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -24.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -30.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Biotechnology Assets was 40.60% per year. The lowest was -67.10% per year. And the median was 4.40% per year.

Biotechnology Assets's current price is €0.344. Its book value per share for the quarter that ended in Dec. 2023 was €0.12. Hence, today's PB Ratio of Biotechnology Assets is 2.97.

During the past 13 years, the highest P/B Ratio of Biotechnology Assets was 12.20. The lowest was 0.58. And the median was 3.36.


Biotechnology Assets Book Value per Share Historical Data

The historical data trend for Biotechnology Assets's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotechnology Assets Book Value per Share Chart

Biotechnology Assets Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.10 0.10 0.07 0.12

Biotechnology Assets Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.08 0.07 0.14 0.12

Competitive Comparison of Biotechnology Assets's Book Value per Share

For the Biotechnology subindustry, Biotechnology Assets's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotechnology Assets's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotechnology Assets's PB Ratio distribution charts can be found below:

* The bar in red indicates where Biotechnology Assets's PB Ratio falls into.



Biotechnology Assets Book Value per Share Calculation

Biotechnology Assets's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6.68-0.00)/57.73
=0.12

Biotechnology Assets's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6.68-0.00)/57.73
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Biotechnology Assets  (XMAD:BST) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Biotechnology Assets Book Value per Share Related Terms

Thank you for viewing the detailed overview of Biotechnology Assets's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotechnology Assets (XMAD:BST) Business Description

Traded in Other Exchanges
N/A
Address
Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.